LeMaitre Vascular (LMAT) Could Be 26% Undervalued On Mixed Valuation Views
LeMaitre Vascular (LMAT) has drawn investor attention after its share price declined about 17% over the past month and about 16% over the past 3 months, prompting fresh questions about valuation and fundamentals.
See our latest analysis for LeMaitre Vascular.
At a share price of US$81.86, LeMaitre Vascular has seen short term momentum fade, with the 30 day share price return down 17.15% and the 1 year total shareholder return down 17.58%, even though the 3 and 5 year total shareholder returns of 48.50% and 52.58% still show longer term gains.
If recent volatility has you reassessing your options, this can be a useful moment to look at other healthcare opportunities and see what stands out in the 41 healthcare AI stocks.
So is LeMaitre Vascular’s recent 17% slide a signal that investors are rethinking the business, or does it mostly reflect a swing in sentiment that has pushed the stock away from its underlying value?
Most Popular Narrative: 25.6% Undervalued
The most followed narrative currently places LeMaitre Vascular’s fair value at $110, which is well above the recent close of $81.86. That gap is built on a detailed set of growth and margin assumptions that go well beyond the latest share price pullback.
Expanding addressable patient population due to global demographic shifts, especially an aging population and increasing prevalence of diabetes and obesity, is likely to drive sustained demand for vascular interventions and LeMaitre's portfolio, supporting ongoing unit sales and top-line revenue expansion over time.
Want to see what sits behind that fair value for LeMaitre Vascular? The narrative leans on steady revenue growth, resilient margins and a future earnings multiple that assumes investors keep paying up for this niche vascular focus. Curious which exact assumptions have the biggest impact on that $110 figure.
Result: Fair Value of $110 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, LeMaitre Vascular still faces execution and pricing risks, including reliance on catheter stocking orders and meaningful price increases that may be harder to sustain.
Find out about the key risks to this LeMaitre Vascular narrative.
Another View on LeMaitre Vascular’s Valuation
The 25.6% undervaluation case for LeMaitre Vascular is built on analyst cash flow and earnings assumptions. The SWS DCF model offers a different perspective. At $81.86, LMAT is trading above its DCF value of $69.97, which indicates the stock is overvalued on this measure. Which lens do you find more convincing?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With sentiment looking mixed on LeMaitre Vascular, it makes sense to review the data yourself and move quickly while the information is fresh. To see the positives our work highlights, start with the 2 key rewards.
Looking for more investment ideas beyond LeMaitre Vascular?
Do not stop with LeMaitre Vascular. Use the Simply Wall St screener to compare different angles, pressure test your thinking and spot ideas others may be overlooking.
- Target potential mispricings by reviewing companies that appear attractively valued using the 48 high quality undervalued stocks.
- Prioritize resilience by focusing on businesses highlighted in the 78 resilient stocks with low risk scores.
- Hunt for tomorrow's potential standouts by scanning the screener containing 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com